Akduman, Ayşe TopçuÖzerkan, KemalZık, BerrinPeker, SabireAvcı, BerrinAta, Barış2024-11-142024-11-142014-12-011309-0399https://doi.org/10.5152/jtgga.2014.14166https://jtgga.org/articles/doi/jtgga.2014.14166https://hdl.handle.net/11452/47868Objective: To determine whether tamoxifen (TMX) exposure causes a permanent decrease in ovarian reserve.Material and Methods: A randomized controlled assessor-blind trial including 30 adult female inbred BALB/C mice. Fifteen mice in the TMX group were given a single 0.1-mg dose of TMX intraperitoneally. Fifteen mice in the control group were given a single dose of the vehicle at the same volume intraperitoneally. Two cycles later, blood samples were collected for determination of anti-Mullerian hormone (AMH) levels, and the mice were sacrificed. After gonadectomy, ovarian size was measured, and follicles were counted under light microscopy.Results: Median serum AMH levels were 6.53 and 6.14 ng/ml in the control and TMX groups, respectively (p=0.03). Ovarian size was significantly decreased in the TMX group. While the number of primordial (9 vs 8), primary (6 vs 3), and secondary (4.5 vs 5) follicles were similar, there were significantly fewer preantral (11.5 vs 6, p<0.01) and antral (2 vs 1, p: 0.03) follicles, as well as corpora lutea (6 vs 3, p: 0.04), in the TMX group than in the control group. The number of atretic (2.5 vs 5, p: 0.048) follicles was increased in the TMX group.Conclusion: Tamoxifen administration leads to arrested growth of gonadotropin-sensitive follicles, while insensitive follicles can remain unaffected. TMX is merely an endocrine disruptor, and it does not cause a decrease in primordial follicle pool.eninfo:eu-repo/semantics/openAccessFollicle-stimulating-hormoneGranulosa-cell differentiationAromatase inhibitorsBreast-cancerEstrogensToxicityGrowthTamoxifenAnti-mullerian hormoneOvarian reserveFolliculogenesisAntral follicle countObstetrics & gynecologyArticle00042067680000622823215410.5152/jtgga.2014.14166